Pfizer`s Lipitor Going to be Ranbaxy`s Generic Lipitor in Canada
Released on = February 1, 2007, 1:15 am
Press Release Author = Brayan Stewert
Industry = Healthcare
Press Release Summary = Now it's very hard time for Pfizer. After the failure of Torcetrapib and patent expiration of lipitor, Pfizer decided to cut jobs.
Press Release Body = Lipitor, the cholesterol lowering drug has been the largest selling drug in 2006.
In 2006 Lipitor accounted 27% of Pfizer's global sales and 30% of its US sales.
The main problem for Pfizer started when it announced lipitor placement with new drug Torcetrapib, this drug was halted due to high number of deaths took place during trial phase.
This was the big problem for Pfizer because Lipitor patent will expire in 2010.
This problem has not yet resolved and another headache for Pfizer has taken place. Ranbaxy an Indian Generic drug maker has planned to produce generic version of lipitor. To protect exclusivity of lipitor Pfizer filed a case in Canada court. The Canadian Federal court ruled against Pfizer last Thursday and denied Pfizer's application to block Ranbaxy from producing a generic Lipitor.
Now it's very hard time for Pfizer. After the failure of Torcetrapib and patent expiration of lipitor, Pfizer decided to cut jobs. Pfizer will cut 10,000 jobs and will close facilities to save on costs.
Pfizer's Profit dropped 43% in the fourth quarter of 2006 as generic products began to make there presence felt.